Printer Friendly

IMMUNEX/LEDERLE MERGER PROXY STATEMENT COMPLETED

 SEATTLE, May 4 /PRNewswire/ -- Immunex Corp. (NASDAQ: IMNX) announced today that the Securities and Exchange Commission has declared effective the joint proxy statement and registration statement for the proposed merger between Immunex and Lederle Oncology Corp., a wholly owned subsidiary of American Cyanamid Co. (NYSE: ACY). Proxy materials will be distributed on or before May 11 to Immunex stockholders of record April 2.
 Immunex will hold a special meeting of stockholders Tuesday, June 1, at 9 a.m. at the Seattle Sheraton Hotel in Seattle at which stockholders will be asked to approve and adopt the agreement and plan of merger between Immunex and Lederle Oncology Corp.
 Immunex Corp. is a biopharmaceutical company focused on the discovery, development, manufacture and marketing of products to treat cancer and autoimmune disease.
 -0- 5/4/93
 /CONTACT: Jason Rubin or Valoree Dowell of Immunex, 206-587-0430/
 (IMNX ACY)


CO: Immunex Corp.; Lederle Oncology Corp.; American Cyanamid Co. ST: Washington IN: MTC SU: TNM

LM -- SE014 -- 4564 05/04/93 17:22 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1993
Words:168
Previous Article:S&P'S STOCK PRICE INDEX -- CLOSING, TUESDAY, MAY 4 /PRN/
Next Article:U.S. EMPLOYERS ENHANCING BENEFITS PROGRAMS WITH CASUAL DRESS POLICIES; JUNE 18 IS UNITED CEREBRAL PALSY CASUAL DAY
Topics:


Related Articles
IMMUNEX ANNOUNCES BUY-BACK OF RECEPTECH; COMPANY WILL EXERCISE ITS PURCHASE OPTION FOR CASH
IMMUNEX REPORTS YEAR-END RESULTS
CYANAMID AND IMMUNEX FORM NEW BIOPHARMACEUTICAL COMPANY; MERGER APPROVED BY IMMUNEX STOCKHOLDERS
IMMUNEX REPORTS SECOND QUARTER RESULTS
IMMUNEX REPORTS THIRD QUARTER RESULTS
IMMUNEX ELECTS EDWARD V. FRITZKY CHAIRMAN AND CHIEF EXECUTIVE OFFICER
IMMUNEX REPORTS 1993 FOURTH QUARTER RESULTS
IMMUNEX REPORTS FIRST QUARTER RESULTS
IMMUNEX SPECIAL COMMITTEE REJECTS AHP OFFER
Immunex Posts Record Sales and Net Income for 2001; ENBREL (R) (etanercept) Tops Expectations at $216 million for Fourth Quarter; ENBREL Reaches $762...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters